As for survival outcomes of the two cohorts, a tendency of an improved OS could be observed in HER2-low-positive BC in comparison with HER2-0 tumor (p=0.097), but no significant difference of BCSS and DFS could be observed between the two groups. This evidence concerns the gene ERBB2 and breast cancer.